Why the study?
The study was designed to evaluate associations between treatment with renin-angiotensin system blockers and the risk of SARS-CoV-2 infection and CoViD-19 severity.
Does ACE inhibitor or ARB treatment increase the risk of SARS-CoV-2 infection or CoViD-19 severity in patients?
Does ACE inhibitor or ARB treatment increase the risk of SARS-CoV-2 infection or CoViD-19 severity in patients?
ACE inhibitors and ARBs do not increase the risk of SARS-CoV-2 infection or severe COVID-19 outcomes, supporting their continued use during the pandemic.
No takes yet. Share an insight, caveat, or question.
Supports continuing RAS blockers during COVID-19; leaves open need for RCTs to confirm safety.
Lee et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: